Chiklita ad
Showing posts with label Pituitary gland. Show all posts
Showing posts with label Pituitary gland. Show all posts
Wednesday, 10 January 2018
Ibuprofen can alter human testicular physiology
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism.
To learn about the impacts of the popular anti-inflammation drug Ibuprofen on male fertility when taken for long periods of time, the researchers asked 31 men between the ages of 18 and 35 to take 600 milligrams (three tablets) a day of the drug for six weeks. Other volunteers were given a placebo. Over the course of the study, the volunteers were tested to see what impact the drug had on their bodies.
The researchers report that just two weeks into the study, they found that all of the volunteers had an increase in luteinizing hormones, which the male body uses to regulate the production of testosterone. The increase indicated that the drug was causing problems in certain cells in the testicles, preventing them from producing testosterone, which is, of course, needed to produce sperm cells.
Change caused the pituitary gland to respond by producing more of another hormone, which forced the body to produce more testosterone. The net result was that overall testosterone levels remained constant, but the body was overstressing to compensate for the detrimental impact of the Ibuprofen-hypogonadism. Compensated hypogonadism can cause a temporary reduction in the production of sperm cells, reducing fertility.
haleplushearty.blogspot.com
Thursday, 28 December 2017
Macrilen for treating growth hormone deficiency
Macrilen (macimorelin) stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Stimulated growth hormone levels are measured in four blood samples over ninety minutes after oral administration of Macrilen (macimorelin) for the assessment of growth hormone deficiency (“GHD”).
Prior to the approval of Macrilen (macimorelin), the historical gold standard for evaluation of AGHD was the insulin tolerance test (“ITT”), an intravenous test requiring many blood draws over several hours. The ITT procedure is inconvenient for patients and medical practitioners and may contraindicate in patients, such as those with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain an accurate result.
Clinical studies have demonstrated that growth hormone stimulation testing for AGHD with oral Macrilen (macimorelin) is reliable, well-tolerated, reproducible, safe and a much simpler test to conduct than currently available options. The availability of Macrilen (macimorelin) will greatly relieve the burden of endocrinologists in reliably and accurately diagnosing AGHD.
haleplushearty.blogspot.com
Subscribe to:
Posts (Atom)

